Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-06-14
2005-06-14
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S514000, C514S269000, C514S256000, C514S561000, C514S482000, C514S617000, C514S473000, C544S244000, C544S297000, C544S298000, C544S322000, C544S330000, C544S335000, C546S001000, C549S263000, C549S295000, C549S321000, C549S323000
Reexamination Certificate
active
06906051
ABSTRACT:
The present invention relates to a class of compounds represented by the Formula I:or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the αVβ3and/or the αVβ5integrin.
REFERENCES:
patent: 5602155 (1997-02-01), Ruminski
patent: 6013651 (2000-01-01), Rogers et al.
patent: 6028223 (2000-02-01), Ruminski et al.
patent: 6211191 (2001-04-01), Duggan et al.
patent: 6720327 (2004-04-01), Ruminski et al.
patent: 0641800 (1994-01-01), None
patent: 9708145 (1997-03-01), None
U.S. Appl. No. 10/381,834, filed Aug. 23, 2003.
Cecil Textbook of Medicine,20thEdition, vol. 1,1004-10(1996).
Uckun et al, Current cancer Drug Targets,1/1,59-71(2001).
PubMed 12082286,also cited as Biorheology,39/1-2,237-46(2002).
PubMed Abstract 12851778,also cited as Acta Neuropathol.(Berl) 106/4,319-22(2003).
PubMed Abstract 12234368,also cited as Immunol. Rev. 186, 125-40(2002).
PubMed Abstract 14718670, also cited as Proc. Natl. Acad. Sci.USA, 101/3,763-8(2004).
PubMed Abstract 10723092, also cited as Cell Biochem. 77/2,265-76(2000).
PubMed Abstract 12657612, also cited as Invest. Ophthalmol. Vis. Sci. 44/4,1704-15(2003).
Carron, et al.,Cancer Research; V. 58, No. 9: pp. 1930-1935; 1998.
Lark, et al.,Journal of Bone&Mineral Research; V. 16, No. 2: pp. 319-327; 2000.
Healy, et al.,Human Reproductive Update; V. 4: pp. 136; 1998.
Cheresh,Cancer Metastasis Review; V. 10: pp. 3-10; 1991.
Brooks, et al.,Cell; V. 79, No. 7: pp. 1157-1164; 1994.
Friedlander, et al.,Proceedings Of The National Academy Of Science USA; V. 93, No. 18; pp. 9764-9769; 1996.
Badger, et al.,Arthritis&Rheumatism; V. 44, No. 1: pp. 128-137; 2001.
Brown,Cardiovascular Research; V. 28; pp. 1815-; 1994.
Friedlander, et al.,Science; V. 270 (5241): pp. 1500-1502; 1995.
Agrez, et al.,Journal of Cell Biology; V. 127, No. 2: pp. 547-556; 1994.
Christofidou-Solomidou, et al.,American Journal of Pathology; V. 151 (4): pp. 975-983; 1997.
Seftor, et al.,Proceedings of the National Academy of Science USA; V. 89: pp. 1557-1561;Mar. 1992.
Montgomery, et al.,Proceedings of the National Academy of Science USA; V. 91: pp. 8856-8860; Sep. 1994.
Adamis, et al.,American Journal of Ophthalmology; V. 118: pp. 445-450; 1994.
Peacock, et al.,Journal of Experimental Medicine; V. 175: pp. 1135-1138; 1992.
Brooks, et al.,Science; V. 264: pp 569-571; 1994.
Sato, et al.,Journal of Cell Biology; V. 111: pp. 1713-1723; 1990.
Fisher, et al.,Endocrinology; V. 132: pp. 1411-1413; 1993.
Choi, et al.,Journal of Vascular Surgery; V. 19(1): pp. 125-134; 1994.
White,Current Biology; V. 3(9): pp 596-599; 1993.
Rodriquez, et al.,Tetrahedron Letters; V. 32(7): pp. 923-926; 1991.
Design in Prodrugs, H. Bundgaard, editor; Elsevier; 1985.
Pytela, et al.,Methods in Enzymology, V. 144: pp. 475-489; 1987.
Yatohgo, et al.,Cell Structure&Function; V. 13: pp. 281-292; 1988.
Charo, et al.,Journal of Biological Chemistry; V. 266(3): pp. 1415-1421; 1991.
Niya, et al.,Blood, V. 70(2): pp. 475-483; 1987.
Rodbard, et al.,International Atomic Energy Agency, Vienna; pp 469-; 1977.
Zucker,Methods in Enzymology; V. 169; pp. 117-133; 1989.
Devadas Balekudru
Jiang Lan
Penning Thomas D.
Rogers Thomas
Ruminiski Peter
Harness Dickey & Pierce LLP
Patel Sudhaker B.
Pharmacia Corporation
Raymond Richard L.
LandOfFree
Lactone integrin antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Lactone integrin antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lactone integrin antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3467928